Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
The Oncologist · 03.06.2024 · 29 (6) · 534-542
DOI: 10.1093/oncolo/oyae022 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 28.02.2024. Verfasst von Thomas Stricker und 17 weiteren Autor:innen. Beteiligte Einrichtung: Tennessee Oncology, Nashville, TN, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Oncogenes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
A recent real-world study observed that 24% of patients with advanced non–small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADOs) initiated nontargeted therapies before biomarker test results became available. This study assessed the clinical impact of the timing of first-line (1L) targeted therapies (TTs) in aNSCLC. Materials and Methods This retrospective analysis of a nationwide electronic health record–derived deidentified database included patients aged ≥18 years diagnosed with aNSCLC with ADOs (ALK, BRAF, EGFR, RET, MET, ROS-1, and NTRK) from January 1, 2015, to October 18, 2022, by biomarker testing within 90 days after advanced diagnosis and received 1L treatment. Cohorts were defined by treatment patterns ≤42 days after test results: “Upfront TT” received 1L TT ≤42 days; “Switchers” initiated 1L non-TT before or after testing but switched to TT ≤42 days; and “Non-switchers” initiated non-TT before or after testing and did not switch at any time. Adjusted multivariate Cox regression evaluated real-world progression-free survival, real-world time to next treatment or death, and real-world overall survival.
Results
A total of 3540 patients met the study criteria; 78% were treated in a community setting, and 50% underwent next-generation sequencing (NGS). There was no significant difference in outcomes between Switchers and Upfront TT; inferior outcomes were observed in Non-switchers versus Upfront TT.
Conclusion
Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tennessee Oncology, Nashville, TN, USA.
- OneOncology LLC, Nashville, TN, USA.
- Genentech, Inc., South San Francisco, CA, USA.
- Mary Bird Perkins Cancer Center, Baton Rouge, LA, USA.
- Eastern Connecticut Hematology and Oncology, Norwich, CT, USA.
- West Cancer Center & Research Institute, Germantown, TN, USA.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Stricker, T., Jain, N., Ma, E., Yu, E., Wang, R., Schuldt, R., Price, R., Szado, T., Sussell, J., Ogale, S., Lin, V., Arrowsmith, E., Slater, D., Vaena, D., Staszewski, H., Fang, B., Seneviratne, L., & Daniel, D. (2024). Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes. The Oncologist, 29(6), 534-542. https://doi.org/10.1093/oncolo/oyae022
Vancouver
Stricker T, Jain N, Ma E, Yu E, Wang R, Schuldt R, et al. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes. The Oncologist. 2024;29(6):534-542. doi:10.1093/oncolo/oyae022
BibTeX
@article{Stricker2024,
author = {Stricker, Thomas and Jain, Neha and Ma, Esprit and Yu, Elaine and Wang, Rongrong and Schuldt, Robert and Price, Richard and Szado, Tania and Sussell, Jesse and Ogale, Sarika and Lin, Victor and Arrowsmith, Edward and Slater, Dennis and Vaena, Daniel and Staszewski, Harry and Fang, Bruno and Seneviratne, Lasika and Daniel, Davey},
title = {Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {6},
pages = {534--542},
doi = {10.1093/oncolo/oyae022}
}
EUVIMED